Key facts
- This page summarizes David E. Wheadon's Form 4 filing for ChemoCentryx, Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 24 Oct 2022, 18:58.
David E. Wheadon - 20 Oct 2022 Form 4 Insider Report for ChemoCentryx, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 20 Oct 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 24 Oct 2022, 18:58:04 UTC
- Prior SEC filing
- 08 Aug 2022
- Next SEC filing
- 31 May 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Susan M. Kanaya, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David E. Wheadon filed Form 4 for ChemoCentryx, Inc. on 24 Oct 2022.
Change
- Previous filing in this sequence was filed on 08 Aug 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CCXI
transaction
Derivative
Restricted Stock Unit
Disposed to Issuer
- Transaction value
- Shares
- -22,274
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 20 Oct 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 22,274
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
David E. Wheadon is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
Reflects the disposition of securities pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 3, 2022, among Amgen Inc. ("Parent"), Carnation Merger Sub, Inc. ("Merger Sub") and ChemoCentryx, Inc. (the "Company"), pursuant to which, on October 20, 2022, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), each restricted stock unit of the Company held by the Reporting Person that was outstanding immediately prior to the Effective Time and that was (A) granted prior to August 3, 2022 or granted after August 3, 2022 and specified in the disclosure schedules delivered by the Company to Parent in connection with the Merger Agreement and/or (B) granted to a non-employee member of the board of directors of the Company became fully vested and was cancelled and converted into the right to receive an amount in cash,
Footnote F2
(Continued from Footnote 1) less applicable withholding taxes and without interest, equal to (x) the total number of shares of common stock, par value $0.001 per share, of the Company underlying such restricted stock unit multiplied by (y) $52.00. The restricted stock units did not have an expiration date.